礼来最新研究公布

Core Viewpoint - Eli Lilly's weight loss drug tirzepatide shows potential in treating obesity with comorbid autoimmune diseases, particularly psoriasis, as demonstrated in a recent study [2][7]. Group 1: Study Results - A late-stage study involving 274 psoriasis patients indicated that the combination of tirzepatide and the existing biologic drug, etanercept, outperformed etanercept alone in efficacy [2][7]. - Approximately 27.1% of patients receiving the combination therapy achieved complete clearance of psoriasis and a 10% weight reduction after 36 weeks, compared to only 5.8% in the etanercept-only group [4][9]. Group 2: Market Competition - Eli Lilly and its main competitor, Novo Nordisk, are engaged in intense competition across multiple markets for new indications of weight loss therapies, which could expand the patient base [4][9]. - Recently, tirzepatide received approval from the National Medical Products Administration in China for use as a monotherapy for adult patients with type 2 diabetes (T2DM) [4][9]. Group 3: Inventory and Approvals - Eli Lilly is preparing for the launch of its oral weight loss drug, with pre-launch inventory reaching $1.5 billion, a significant increase from $550 million the previous year [5][9]. - In Europe, Novo Nordisk's weight loss drug semaglutide 7.2mg received approval, providing more treatment options for doctors and patients [5][9].